Department of Defense scraps $20 million VaxSyn trial

Department of Defense scraps $20 million VaxSyn trial

WASHINGTON -- The Department of Defense has decided to scrap a planned $20 million Phase III clinical trial of MicroGeneSys Inc.'s VaxSyn (gp160) AIDS vaccine, and instead use the money to fund a vaccine therapy development program.

The U.S. Army Medical Research

Read the full 499 word article

How to gain access

Continue reading with a
two-week free trial.